Overview

* Editas Q2 net loss at $53.2 mln, missing analyst expectations

* Collaboration and R&D revenues rise significantly due to milestone payments

* Operating expenses decrease following reni-cel program discontinuation

Outlook

* Company plans to file IND by mid-2026

* Company expects cash runway into Q2 2027

Result Drivers

* COLLABORATION REVENUE - Increase in collaboration and R&D revenues driven by milestone payments from Bristol Myers Squibb partnership

* PRECLINICAL DATA - New proof-of-concept data presented for gene upregulation strategy and in vivo delivery platform

* EXPENSE REDUCTION - Decrease in R&D expenses due to discontinuation of reni-cel program

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $3.60

Collabor mln

ation

and

other

research

and

developm

ent

revenue

Q2 EPS -$0.63

Q2 Net Miss -$53.24 -$33.40

Income mln mln (9

Analysts

)

Q2 Basic -$0.63

EPS

Q2 $55.12

Operatin mln

g

Expenses

Q2 -$51.54

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Editas Medicine Inc ( EDIT ) is $3.50, about 37.1% above its August 11 closing price of $2.20

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)